Research Summary

Zoe is an endocrinologist at UCSF and the San Francisco VA with particular interest in endocrine autoimmune disease and endocrine complications of cancer treatments, particularly immunotherapy.

Education

BA, - Biology, Brown University
Residency, - Internal Medicine, Stanford Hospital and Clinics
MS, - Health and Medical Sciences, UC Berkeley
Fellowship, - Endocrinology and Diabetes, UCSF
MD, - Medical School, UCSF

Selected Publications

  1. Sharon E, Othus M, Quandt ZE. Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having. Cancer. 2023 Jul 13.  View on PubMed
  2. Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. Oncologist. 2023 Jun 19.  View on PubMed
  3. Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e24091-e24091.  View on PubMed
  4. Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt. The cognitive load of inpatient consults involving immune-related adverse events. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):11033-11033.  View on PubMed
  5. Middha P, Thummalapalli R, Betti MJ, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy. medRxiv. 2023 May 16.  View on PubMed
  6. Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. J Endocr Soc. 2023 Feb 09; 7(4):bvad012.  View on PubMed
  7. Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol. 2023 05; 41(5):717-727.  View on PubMed
  8. Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes. 2023 01 01; 72(1):59-70.  View on PubMed
  9. Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY, Tagi VM, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kämpe O, Dobbs K, Delmonte OM, Bacchetta R, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL. Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq. Elife. 2022 10 27; 11.  View on PubMed
  10. Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder. Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP). Journal of Clinical Oncology. 2022 Sep 30; 40(28_suppl):422-422.  View on PubMed
  11. Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022 09 08; 7(17).  View on PubMed
  12. ZOE QUANDT, ARABELLA YOUNG, GRAHAM BARLOW, SHEN DONG, JENNIFER SMITH, IRINA KUSMARTSEVA, TODD M. BRUSKO, STEWART COOPER, MARK S. ANDERSON. 189-OR: Immune-Profiling of Pancreatic Tissue Affected by Immune Checkpoint Inhibitor–Induced Diabetes (CPI-D). Diabetes. 2022 Jun 1; 71(Supplement_1).  View on PubMed
  13. Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield. Evaluating survival following severe immune-related adverse events requiring hospitalization. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):2666-2666.  View on PubMed
  14. Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon. Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):2668-2668.  View on PubMed
  15. Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Mandel-Brehm C, Miao B, Sowa G, Zorn K, Chan AY, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kampe O, Dobbs K, Delmonte OM, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL. Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq. bioRxiv. 2022 Mar 24.  View on PubMed
  16. Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME. Patient-Centered Diabetes Care of Cancer Patients. Curr Diab Rep. 2021 12 13; 21(12):62.  View on PubMed
  17. Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140.  View on PubMed
  18. Zoe Quandt, Paras Mehta, Katy Tsai, Victoria Hsiao, Robert Rushakoff. Case 20: Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes. . 2021 Jan 1; 80-82.  View on PubMed
  19. Paras Mehta, Zoe Quandt, Robert Rushakoff. Case 21: Checkpoint Inhibitor–Induced Diabetes. . 2021 Jan 1; 83-85.  View on PubMed
  20. Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS. Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. Annu Rev Med. 2021 01 27; 72:313-330.  View on PubMed

Go to UCSF Profiles, powered by CTSI